I think you still need a little bit patience. PSMA ADC data are important because this is not typical phase I study, it includes almost one year follow up. This is short term catalyst.
Sales can do much better under SLXP with prefilled syringe, but it will be a gradual process. The bigger catalysts are Relistor approval in general population in 2012, which should ramp up revenue significantly, and oral Relistor phase III trial result.
I try not to predict biotech stock price. They can swing sharply without much logic.
Market Data 
Markets 
AI
